GENinCode (LON:GENI) Shares Up 16.2% – What’s Next?

GENinCode Plc (LON:GENI) traded up 16.2% during mid-day trading on Tuesday. The company traded as high as GBX 0.70 and last traded at GBX 0.70. Approximately 3,865,641 shares traded hands during trading, a decline of 21% from the average daily volume of 4,872,882 shares. The stock had previously closed at GBX 0.60.

GENinCode Trading Up 1.3%

The company has a market capitalization of £4.67 million, a price-to-earnings ratio of -0.49 and a beta of 0.59. The firm has a 50-day moving average price of GBX 0.83 and a 200-day moving average price of GBX 0.94. The company has a current ratio of 2.22, a quick ratio of 15.88 and a debt-to-equity ratio of 4.75.

GENinCode (LON:GENI) last posted its quarterly earnings data on Tuesday, September 29th. The company reported GBX (0.38) EPS for the quarter. GENinCode had a negative return on equity of 481.34% and a negative net margin of 202.42%. As a group, sell-side analysts predict that GENinCode Plc will post -7.13 EPS for the current year.

About GENinCode

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.